Exenatide may improve maintenance of HbA1c targets, with less hypoglycaemia, but more early adverse effects when compared with low-dose glimepiride
- PMID: 23474698
- DOI: 10.1136/eb-2013-101248
Exenatide may improve maintenance of HbA1c targets, with less hypoglycaemia, but more early adverse effects when compared with low-dose glimepiride
Comment on
-
Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial.Lancet. 2012 Jun 16;379(9833):2270-8. doi: 10.1016/S0140-6736(12)60479-6. Epub 2012 Jun 9. Lancet. 2012. PMID: 22683137 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical